CTRN

Citi Trends, Inc.

56
Fundamentals60/ 100
Valuation30/ 100
Upside potential65/ 100
Risk potential26/ 100

CTRN has a slight edge over NIO overall, supported by stronger modeled upside and lower modeled downside.

NIO

NIO Inc.

56
Fundamentals77/ 100
Valuation50/ 100
Upside potential58/ 100
Risk potential27/ 100

NIO offers stronger valuation, but that advantage does not outweigh its weaker overall profile.

CTRN Fundamentals

MetricStatus
Healthy
Healthy
Stable
Strong

CTRN's revenue, profitability and balance sheet are currently healthy, and its cash flow is stable.

NIO Fundamentals

MetricStatus
Strong
Stable
Stable
Unavailable

NIO's revenue is currently strong, and its profitability and cash flow are stable. There isn't enough data to rate its balance sheet.

CTRN PE Valuation

CHEAPFAIREXPENSIVE22x43x65x86x
CHEAPFAIREXPENSIVE22x43x65x86x
LevelPEPriceVs current
Cheap3.8x$3.31-92%
Fair10x$8.73-80%
Forward19x$43.05—
Expensive46x$39.40-8.5%
Current50x$43.05—

Historical ranges are pointers, not guarantees.

CTRN's PE is in its expensive range at 50x. If earnings grow as analysts expect, today's price would be 19x next year's earnings, in its fair range.

NIO PE Valuation

NIO has no meaningful PE right now: it lost money over the past year.

CTRN Forward outlook

MetricOutlook
Strongly improving
Strong growth
Growth
Improving
Limited
High

Analysts expect earnings and revenue growth for CTRN, with profitability improving.

NIO Forward outlook

MetricOutlook
--
Losses shrinking
Growth
Strongly improving
Limited
Moderate

Analysts expect NIO's losses to shrink, with revenue growing.

CTRN Risk to reward

ScenarioChangePrice
Upside+47%$63.44
Downside-26%$31.99

Calculated from the latest close: $43.05 on Nov 12.

CTRN has a better modeled risk to reward balance than NIO, with more potential upside and less potential downside.

NIO Risk to reward

ScenarioChangePrice
Upside+38%$4.21
Downside-27%$2.22

Calculated from the latest close: $3.05 on Nov 12.

NIO trails CTRN on modeled risk to reward, with less potential upside and more potential downside.

CTRN Earnings Per Share

Q4 2023: $-1.02Q1 2024: $-1.46Q2 2024: $-1.07Q3 2024: $-2.67Q4 2024: $-3.06Q1 2025: $-5.19Q2 2025: $-4.66Q3 2025: $-1.99Q4 2025: $-1.99Q1 2026: $0.63Q2 2026: $1.43Q3 2026: $0.86Forward: $2.33
Q4 2023: $-1.02Q1 2024: $-1.46Q2 2024: $-1.07Q3 2024: $-2.67Q4 2024: $-3.06Q1 2025: $-5.19Q2 2025: $-4.66Q3 2025: $-1.99Q4 2025: $-1.99Q1 2026: $0.63Q2 2026: $1.43Q3 2026: $0.86Forward: $2.33
QuarterTTM EPSYoY
Forward$2.33+170%
Q3 2026$0.86+$2.85
Q2 2026$1.43+$6.09
Q1 2026$0.63+$5.82
Q4 2025-$1.99+$1.07
Q3 2025-$1.99+$0.68
Q2 2025-$4.66-$3.59
Q1 2025-$5.19-$3.73
Q4 2024-$3.06-$2.04

CTRN has the edge over NIO on earnings quality, reporting a profit while its opponent remains loss making.

NIO Earnings Per Share

Q3 2023: $-1.93Q4 2023: $-1.87Q1 2024: $-1.82Q2 2024: $-1.64Q3 2024: $-1.61Q4 2024: $-1.66Q1 2025: $-1.76Q2 2025: $-1.74Q3 2025: $-1.59Q4 2025: $-1.06Q1 2026: $-0.60Q2 2026: $-0.29
Q3 2023: $-1.93Q4 2023: $-1.87Q1 2024: $-1.82Q2 2024: $-1.64Q3 2024: $-1.61Q4 2024: $-1.66Q1 2025: $-1.76Q2 2025: $-1.74Q3 2025: $-1.59Q4 2025: $-1.06Q1 2026: $-0.60Q2 2026: $-0.29
QuarterTTM EPSYoY
Q2 2026-$0.29+$1.45
Q1 2026-$0.60+$1.16
Q4 2025-$1.06+$0.60
Q3 2025-$1.59+$0.02
Q2 2025-$1.74-$0.10
Q1 2025-$1.76+$0.06
Q4 2024-$1.66+$0.21
Q3 2024-$1.61+$0.32

NIO is still losing money, but far less than before: $0.29 per share over the past year, against $1.93 at its worst in late 2023.

CTRN Quarterly Revenue

Q4 2023: $180MQ1 2024: $215MQ2 2024: $186MQ3 2024: $177MQ4 2024: $179MQ1 2025: $211MQ2 2025: $202MQ3 2025: $191MQ4 2025: $197MQ1 2026: $230MQ2 2026: $231MQ3 2026: $212M
Q4 2023: $180MQ1 2024: $215MQ2 2024: $186MQ3 2024: $177MQ4 2024: $179MQ1 2025: $211MQ2 2025: $202MQ3 2025: $191MQ4 2025: $197MQ1 2026: $230MQ2 2026: $231MQ3 2026: $212M
QuarterRevenueYoY
Q3 2026$211.6M+11%
Q2 2026$230.9M+14%
Q1 2026$230.4M+9.1%
Q4 2025$197.1M+10%
Q3 2025$190.8M+8%
Q2 2025$201.7M+8.3%
Q1 2025$211.2M-1.9%
Q4 2024$179.1M-0.3%

CTRN's revenue is recovering but still below its 2021 peak: $212M last quarter, up 11% from the same quarter a year ago.

NIO Quarterly Revenue

Q3 2023: $2.9BQ4 2023: $2.6BQ1 2024: $1.5BQ2 2024: $2.6BQ3 2024: $2.8BQ4 2024: $3BQ1 2025: $1.8BQ2 2025: $2.9BQ3 2025: $3.3BQ4 2025: $5.2BQ1 2026: $3.8BQ2 2026: $4.8B
Q3 2023: $2.9BQ4 2023: $2.6BQ1 2024: $1.5BQ2 2024: $2.6BQ3 2024: $2.8BQ4 2024: $3BQ1 2025: $1.8BQ2 2025: $2.9BQ3 2025: $3.3BQ4 2025: $5.2BQ1 2026: $3.8BQ2 2026: $4.8B
QuarterRevenueYoY
Q2 2026$4.8B+69%
Q1 2026$3.8B+112%
Q4 2025$5.2B+76%
Q3 2025$3.3B+17%
Q2 2025$2.9B+9%
Q1 2025$1.8B+21%
Q4 2024$3B+15%
Q3 2024$2.8B-2.1%

NIO has the edge over CTRN on sales, with more consistent year-over-year improvement.

CTRN Free Cash Flow

Q4 2023: −$8MQ1 2024: $20MQ2 2024: −$21MQ3 2024: $2MQ4 2024: −$20MQ1 2025: $26MQ2 2025: −$13MQ3 2025: −$2MQ4 2025: $767,000Q1 2026: $15MQ2 2026: $15MQ3 2026: −$24M
Q4 2023: −$8MQ1 2024: $20MQ2 2024: −$21MQ3 2024: $2MQ4 2024: −$20MQ1 2025: $26MQ2 2025: −$13MQ3 2025: −$2MQ4 2025: $767,000Q1 2026: $15MQ2 2026: $15MQ3 2026: −$24M
QuarterFree cash flowYoY
Q3 2026-$24M-$22.2M
Q2 2026$15M+$28.1M
Q1 2026$14.7M-44%
Q4 2025$767K+$21.2M
Q3 2025-$1.7M-205%
Q2 2025-$13.1M+$8.1M
Q1 2025$26M+30%
Q4 2024-$20.4M-$12.8M

CTRN's free cash flow has turned positive after four years mostly in the red: $6M over the past year.

NIO Free Cash Flow

Q3 2023: --Q4 2023: $137MQ1 2024: $0Q2 2024: −$2.2BQ3 2024: $0Q4 2024: −$391MQ1 2025: $0Q2 2025: −$2.1BQ3 2025: $0Q4 2025: $0Q1 2026: $0Q2 2026: $0
Q3 2023: --Q4 2023: $137MQ1 2024: $0Q2 2024: −$2.2BQ3 2024: $0Q4 2024: −$391MQ1 2025: $0Q2 2025: −$2.1BQ3 2025: $0Q4 2025: $0Q1 2026: $0Q2 2026: $0
QuarterFree cash flowYoY
Q2 2026$0+$2.1B
Q1 2026$0$0
Q4 2025$0+$391.3M
Q3 2025$0$0
Q2 2025-$2.1B+$73.9M
Q1 2025$0$0
Q4 2024-$391.3M-386%
Q2 2024-$2.2B+$337.9M

NIO's free cash flow was $0 over the past year, against −$2.5B the year before.

CTRN Total Shares

Q4 2023: 8MQ1 2024: 8MQ2 2024: 8MQ3 2024: 8MQ4 2024: 8MQ1 2025: 8MQ2 2025: 8MQ3 2025: 8MQ4 2025: 8MQ1 2026: 8MQ2 2026: 8MQ3 2026: 8M
Q4 2023: 8MQ1 2024: 8MQ2 2024: 8MQ3 2024: 8MQ4 2024: 8MQ1 2025: 8MQ2 2025: 8MQ3 2025: 8MQ4 2025: 8MQ1 2026: 8MQ2 2026: 8MQ3 2026: 8M
PeriodChange %Net change
Quarterly-3.5%-301K shares
1 year-1.6%-130K shares
3 years-0.5%-41.4K shares
5 years-11%-995K shares
Available history-30%-3.5M shares

CTRN has the edge over NIO on shareholder dilution, with a more favorable share count trend.

NIO Total Shares

Q3 2023: 1.7BQ4 2023: 1.8BQ1 2024: 2BQ2 2024: 2BQ3 2024: 2.1BQ4 2024: 2.1BQ1 2025: 2.1BQ2 2025: 2.2BQ3 2025: 2.4BQ4 2025: 2.5BQ1 2026: 2.5BQ2 2026: 2.5B
Q3 2023: 1.7BQ4 2023: 1.8BQ1 2024: 2BQ2 2024: 2BQ3 2024: 2.1BQ4 2024: 2.1BQ1 2025: 2.1BQ2 2025: 2.2BQ3 2025: 2.4BQ4 2025: 2.5BQ1 2026: 2.5BQ2 2026: 2.5B
PeriodChange %Net change
Quarterly+0.6%+15.6M shares
1 year+12%+267M shares
3 years+51%+844M shares
5 years+60%+933M shares
Available history+143%+1.5B shares

NIO has 2.5B diluted shares, up 12% from a year ago.

CTRN Net Leverage

Q4 2023: -20.2xQ2 2024: -27.2xQ3 2025: -3.5xQ4 2025: -3.2xQ1 2026: -3.0xQ2 2026: -2.7xQ3 2026: -2.2x
Q4 2023: -20.2xQ2 2024: -27.2xQ3 2025: -3.5xQ4 2025: -3.2xQ1 2026: -3.0xQ2 2026: -2.7xQ3 2026: -2.2x
QuarterNet LeverageStatus
Q3 2026-2.2xNet Cash
Q2 2026-2.7xNet Cash
Q1 2026-3.0xNet Cash
Q4 2025-3.2xNet Cash
Q3 2025-3.5xNet Cash
Q2 2024-27.2xNet Cash
Q4 2023-20.2xNet Cash
Q3 2023-1.6xNet Cash

CTRN has more cash than debt.

NIO Net Leverage

NIO's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.

CTRN Weekly Momentum

MetricValueStatus
RSI39.5Neutral
Stochastic6.0Oversold

CTRN's weekly RSI is 39 (neutral) and its Stochastic is 6 (oversold).

NIO Weekly Momentum

MetricValueStatus
RSI30.7Neutral
Stochastic6.9Oversold

NIO's weekly RSI is 31 (neutral) and its Stochastic is 7 (oversold).

CTRN PE vs Consumer Cyclical Sector

MetricCTRNSector medianRelative
PE50x18x178% above
PE %864739 pts above

CTRN is trading at 50x earnings, a 178% premium to the Consumer Cyclical sector's median of 18x.

NIO PE vs Consumer Cyclical Sector

NIO has no meaningful PE right now: it lost money over the past year.

CTRN Weekly Moving Averages

Moving averageMA priceRelative
8 week MA$47.49.1% below
20 week MA$57.926% below
50 week MA$50.815% below
100 week MA$40.17.4% above
200 week MA$31.238% above

CTRN has the edge over NIO on trend strength, trading above more of its moving averages.

NIO Weekly Moving Averages

Moving averageMA priceRelative
8 week MA$3.369.2% below
20 week MA$4.0124% below
50 week MA$4.8137% below
100 week MA$4.8537% below
200 week MA$6.0349% below

NIO is in a downtrend: it's below all five of its weekly moving averages, and 49% below its 200-week average.

CTRN Yearly ROI

YearStart priceEnd priceROI
2020$22.8$47.4+108%
2021$47.4$76.4+61%
2022$76.4$27.6-64%
2023$27.6$28.3+2.4%
2024$28.3$26.9-5.1%
2025$26.9$40.2+50%
2026 YTD$40.2$43.1+7.2%

CTRN has the edge over NIO on returns for 2026, with the stronger performance.

NIO Yearly ROI

YearStart priceEnd priceROI
2020$2.42$45.8+1791%
2021$45.8$30.5-33%
2022$30.5$11.0-64%
2023$11.0$9.07-17%
2024$9.07$4.48-51%
2025$4.48$5.10+14%
2026 YTD$5.10$3.05-40%

NIO's yearly returns have swung widely, from +1791% in 2020 to −64% in 2022. It's down 40% so far in 2026.

Give your agent the market.

Get API key